A new drug to treat asthma, jointly developed by Shenyang Pharmacy University and Jinzhou Jiutai Pharmaceuticals, was granted on August 18 an approval for Phase I clinical trials issued by the State Food and Drug Administration. The new drug presents a strong suppressing effect on asthma, with long duration. Compared with similar drugs, it produces less but claims a higher safety.
The new drug had applied for a national invention patent in 2001, and entered a PCT process in 2002. So far it has completed patent registrations in the United States, Europe, Japan, Russia, India, and Hong Kong, and obtained a patent grant in Russia. The drug, once hit the market, expects a promising annual output worth RMB 200 million, with a profit and tax payment at RMB 62 million.
|
